Brought to you by 
Core Group PLC acquires CeNeS in reverse merger
10 Apr 2000
Executive Summary
Core Group PLC (drug delivery) has acquired privately held UK biotech company CeNeS Ltd. (central nervous system therapeutics) in a reverse merger--for about $30mm (UK18.4mm) in stock--in order to take CeNeS public. Core has issued approximately 53mm common shares to CeNeS's current shareholders, giving them 64.7% of the merged company, which will be named CeNeS Pharmaceuticals PLC and have a listing on the London Stock Exchange.
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Core Group PLC acquires CeNeS in reverse merger
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice